Nexalin Technology (NXL) Debt Ratio (2021)

Nexalin Technology's (NXL) quarterly Debt Ratio came in at 0.08 in Q4 2021.

Nexalin Technology (NXL) Debt Ratio (2021) Analysis & Trends

Nexalin Technology's Debt Ratio history runs 1 years deep, the most recent figure standing at 0.08 for Q4 2021.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.08 in Q4 2021; TTM through Dec 2021 was 0.08, a N/A change from a year earlier, with the FY2021 full-year figure at 0.08, changed N/A from the prior year.
Debt Ratio was little changed at 0.08 in Q4 2021 per NXL's latest filing.
Across five years, Debt Ratio topped out at 0.08 in Q4 2021 and bottomed at 0.08 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	0.31
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	0.32
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	0.30
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	0.04
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	0.30
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	0.27
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	0.30
10	Nexalin Technology	9.32 Mn	6.61 Mn	13,133.00	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	0.08